Acute Sinusitis Market to Reach USD 3,521.81 Million by 2026 at a CAGR of 7.1%

Introduction

Acute Sinusitis, also referred as rhinosinusitis, is a short-term inflammation of the membranes that lines around the nose and sinuses. This medical condition hampers the ability of draining mucus from the nose and sinuses. Surging prevalence and growing number of patient suffering from acute sinusitis across the globe drives the growth of the market. Moreover, inclining usage of over the counter medications such as decongestants, nasal sprays and nasal corticosteroids are also anticipated to fuel the growth of the market during the forecast period 2019–2026.Moreover, Sinusitis is considered to be acute if it lasts longer than 4-30 days and sub-acute if continues from 4–12 weeks. Besides, it is not common to develop sinuses. The condition can be prevented by maintaining healthy eating habits, hygiene, and by avoiding cigarette smoke.

Market Segmentation

The global acute sinusitis market is segmented by treatment, end-user, and region.

On the basis of treatment, the market is segmented into diagnosis and medication. Diagnosis is further segmented into imaging test, allergy test, nasal endoscopy, and laboratory test. Imaging is further segregated into computed tomography and magnetic resonance imaging. Medication is segmented into saline nasal spray, nasal corticosteroids, decongestant, antibiotics, OTC pain relievers, allergy shots and others. The medication segment is expected to hold major market share as sinus treatment takes a long time as compared to one-time diagnosis. In addition, huge population suffering from acute sinusitis is projected to support the growth of the medication segment during the forecast period 2019–2026.

By end-use, the market is segmented into hospitals & clinics, ENTC specialist, research institutes, and others. Hospital & clinics is holding the major market share because of frequent visits, and emergency departments. Nevertheless, ENTC specialist is the fastest growing segment and is expected to flourish in the coming years following increasing awareness, changing preferences, and rising shift towards specialists.

Regional Analysis

The global acute sinusitis market regionally is segmented into North America, Europe, Asia-Pacific and Latin America, the Middles East & Africa.

In Europe, several governments are investing heavily in the R&D activities and technological advancements for healthcare diagnostic. In January 2019, San Francisco developed ClearUP device for treating sinus pain. Commonly, it is used to deliver electric current to the nose by sliding the device along the outside of the nasal passages during the therapy.

Asia Pacific is the fastest growing market following the increasing prevalence of acute sinusitis population in the region. As per the WHO, in India, high prevalence of asthma, COPD diseases is boosting the market growth in the region. Besides, increasing awareness among people about acute sinusitis, huge developments in the pharmaceutical industry, expanding infrastructure of healthcare institutes such as hospitals & clinics, diagnostic laboratories, pharmaceutical companies, and availability of trained professionals majorly in India, China and Japan contributes to the growth of the APAC.

The global acute sinusitis market has huge presence of local and international players and the competition is increasing in terms of product uniqueness, competitive pricing, online and off-line servicing, and upgrading technology and imaging software. It is expected that the competitive environment of the market is likely to heat up due to the existence of several global and local manufacturers and imaging solution providers.

Competitive Players

1. Sanofi (France)
2. Bristol-Myers Squibb (U.S.)
3. Reddy’s Laboratory (India)
4. Eli Lilly and Company (U.S.)
5. Abbott (U.S.)
6. Bayer AG(Germany)
7. Novartis AG(Switzerland)
8. AstraZeneca Plc. (U.K.)
9. Merck & Co, Inc. (U.S.)

Recent Developments

• February 2022- Olympus, a global leader in inventing and delivering breakthrough solutions for medical and surgical operations, announced that its CELERISTM single-use sinus debride system has received FDA certification and will soon be available on the market. The CELERIS system is designed for cutting, coagulation, debridement, and removal of thin bone and soft tissue in general ENT and sinus/rhinology treatments.
• July 2021- GlaxoSmithKline (GSK) stated that the Food and Drug Administration (FDA) had authorized Nucala (mepolizumab) as a therapy for individuals with chronic rhinosinusitis with nasal polyps. This is a new indication for the monoclonal antibody mepolizumab, which targets interleukin-5 (IL-5).
• August 2021- The European Commission (EC) authorized Xolair (omalizumab) as add-on therapy with intranasal corticosteroids (INC) for the treatment of people (18 years and older) with severe chronic rhinosinusitis with nasal polyps for whom therapy INC does not offer satisfactory disease control.

Segmentation

1. By Treatment
   1. Diagnosis
   2. Medication
2. By End-User
   1. Hospitals & Clinics
   2. ENTC Specialists
   3. Research Institute
   4. Others